May 1, 2017 / 12:57 PM / in 6 months

BUZZ-Aeterna Zentaris: Plunges after cancer drug fails late-stage study

** Canadian drug developer’s U.S.-listed shares slump 58 pct to $1.40 in heavy premarket trading; set to open at record low

** AEZS is second-biggest pct loser among Nasdaq-listed stocks

** Co says its drug, Zoptrex, to treat endometrial cancer, failed to achieve main goal of a late-stage study

** Zoptrex was tested in women with locally advanced, recurrent or metastatic endometrial cancer

** Endometrial cancer is a cancer that arises from the lining of the uterus or womb

** Up to Friday’s close, stock had fallen 20 pct in last 12 months

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below